{"id":"ldac-and-or-mitoxantrone","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Cardiotoxicity (mitoxantrone-related)"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":{"chemblId":"CHEMBL1417019","moleculeType":"Small molecule","molecularWeight":"517.41"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Low-dose cytarabine is a nucleoside analog that incorporates into DNA and inhibits DNA polymerase, while mitoxantrone is a topoisomerase II inhibitor that causes DNA strand breaks. Together, they are used in combination chemotherapy regimens to treat acute myeloid leukemia and other hematologic malignancies by inducing apoptosis in leukemic blasts.","oneSentence":"LDAC (low-dose cytarabine) and mitoxantrone are chemotherapy agents that inhibit DNA synthesis and topoisomerase II, respectively, to kill rapidly dividing leukemic cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:18:31.098Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia (AML), particularly in elderly or unfit patients"},{"name":"Relapsed or refractory acute leukemia"}]},"trialDetails":[{"nctId":"NCT02920008","phase":"PHASE3","title":"Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2017-03-16","conditions":"Acute Myeloid Leukemia","enrollment":302},{"nctId":"NCT02907359","phase":"PHASE3","title":"Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2017-01-13","conditions":"Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic","enrollment":417},{"nctId":"NCT02461537","phase":"PHASE3","title":"Impact of Remission Induction Chemotherapy Prior to Allogeneic SCT in Relapsed and Poor-response Patients With AML","status":"COMPLETED","sponsor":"DKMS gemeinnützige GmbH","startDate":"2015-09-17","conditions":"Acute Myeloid Leukemia","enrollment":281},{"nctId":"NCT00136084","phase":"PHASE3","title":"Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2002-08","conditions":"Leukemia, Myelocytic, Acute","enrollment":238}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6093,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"LDAC and/or Mitoxantrone","genericName":"LDAC and/or Mitoxantrone","companyName":"DKMS gemeinnützige GmbH","companyId":"dkms-gemeinn-tzige-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LDAC (low-dose cytarabine) and mitoxantrone are chemotherapy agents that inhibit DNA synthesis and topoisomerase II, respectively, to kill rapidly dividing leukemic cells. Used for Acute myeloid leukemia (AML), particularly in elderly or unfit patients, Relapsed or refractory acute leukemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}